A Phase Ia Single-center,Randomized,Double-blind,Placebo-controled Study to Investigate the Safety, Tolerability, Pharmacokinetics of Single and Multiple Doses of Hepenofovir Fumarate Tablets in Healthy Volunteers
Latest Information Update: 03 Feb 2022
At a glance
- Drugs Hepenofovir fumarate (Primary)
- Indications Hepatitis B
- Focus Adverse reactions
- Sponsors Xian Xintong Pharmaceutical Research
Most Recent Events
- 27 Feb 2020 New trial record